Key clinical point: The total cost of care for patients with metastatic castration-resistant prostate cancer (mCRPC) is significantly higher than patients with non-metastatic CRPC.
Major finding: Total all-cause health care costs increased 6.2-fold from the nmCRPC to mCRPC periods in commercially insured patients, and among Medigap patients the costs increased 5.1-fold from the nmCRPC to mCRPC periods.
Study details: This retrospective, cohort study captured data from insurance claims from male patients aged ≥18 years between 2012-2016.
Wu B, et al. J Med Econ. 2019 Oct 7:1. doi: 10.1080/13696998.2019.1678171.